Product Pipeline
At Regulus, we are creating a new class of high-impact medicines based on microRNA. Regulus is advancing microRNA therapeutics in several areas including hepatitis C infection, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases.
Regulus is leading the development of RNA-based therapeutics targeting microRNA and believes that microRNAs will become a major part of pharmaceutical drug development efforts.
